New soluble CSF-1R-dimeric mutein with enhanced trapping of both CSF-1 and IL-34 reduces suppressive tumor-associated macrophages in pleural mesothelioma
Journal for ImmunoTherapy of Cancer · 2025-03 · 13 (3) · e010112
DOI: 10.1136/jitc-2024-010112 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 17.03.2025. Verfasst von Noémie Joalland und 12 weiteren Autor:innen. Beteiligte Einrichtung: INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, Nantes Universite, Nantes, France. Hauptthemen laut MEDLINE: Macrophage Colony-Stimulating Factor, Tumor-Associated Macrophages, Interleukins, Mesothelioma. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Labex, Fondation ARC pour la Recherche sur le Cancer, French national research agency.
Abstract (Originalsprache)
Background
Colony stimulating factor-1 receptor (CSF-1R) and its ligands CSF-1 and interleukin (IL)-34 have tumorigenic effects through both induction of suppressive macrophages, and survival/proliferation of tumor cells. In addition, the IL-34 tumorigenic effect can also be mediated by its other receptors, protein-tyrosine phosphatase zeta, Syndecan-1 (CD138) and triggering receptor expressed on myeloid cells 2. Small tyrosine kinase inhibitors are used to block CSF-1R signaling but lack specificity. Neutralizing anti-CSF-1 and/or IL-34 antibodies have been proposed, but their effects are limited. Thus, there is a need for a more specific and yet integrative approach.
Methods
A human mutated form of the extracellular portion of CSF-1R was in silico modelized to trap both IL-34 and CSF-1 with higher affinity than the wild-type CSF-1R by replacing the methionine residue at position 149 with a Lysine ( M149K ). The extracellular portion of the mutated CSF-1R M149K was dimerized using the immunoglobulin Fc sequence of a silenced human IgG1 (sCSF-1R M149K -Fc). Signaling through CSF-1R, survival of monocytes and differentiation of suppressive macrophages were analyzed using pleural mesothelioma patient's samples and mesothelioma/macrophage spheroids in vitro and in vivo in the presence of sCSF-1R M149K -Fc or sCSF-1R-Fc wild type control (sCSF-1R WT -Fc).
Results
We defined that the D1 to D5 domains of the extracellular portion of CSF-1R were required for efficient binding to IL-34 and CSF-1. The mutein sCSF-1R M149K -Fc trapped with higher affinity than sCSF-1R WT -Fc both CSF-1 and IL-34 added in culture and naturally produced in mesothelioma pleural effusions. sCSF-1R M149K -Fc inhibited CSF-1R signaling, survival and differentiation of human suppressive macrophage in vitro and in vivo induced by pleural mesothelioma cells. Neutralization of IL-34 and CSF-1 by sCSF-1R M149K -Fc also resulted in higher killing of pleural mesothelioma cells by a tumor-specific CD8 + T cell clone in mesothelioma/macrophage spheroids. Conclusions sCSF-1R M149K -Fc efficiently traps both CSF-1 and IL-34 and inhibits CSF-1R signaling, monocyte survival and suppressive macrophage differentiation induced by pleural mesothelioma cells producing CSF-1 and IL-34, as well as restores cytotoxic T-cell responses. sCSF-1R M149K -Fc has therapeutic potential vs other therapies under development targeting single components of this complex cytokine pathway involved in cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, Nantes Universite, Nantes, France.
- LabEx IGO, Nantes Université, Nantes, France.
- INSERM, UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, University of Nantes, Nantes, France.
- INSERM, CNRS, SFR Bonamy, UMS BioCore, Imp@ct Platform, Nantes Université, Centre Hospitalo-Universitaire (CHU) Nantes, Nantes, France.
- INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, Nantes Universite, Nantes, France ianegon@nantes.inserm.fr carole.guillonneau@univ-nantes.fr.
Förderung
- Labex
- Fondation ARC pour la Recherche sur le Cancer
- French national research agency
Zitieren
APA
Joalland, N., Quéméner, A., Deshayes, S., Humeau, R., Maillasson, M., LeBihan, H., Salama, A., Fresquet, J., Remy, S., Mortier, E., Blanquart, C., Guillonneau, C., & Anegon, I. (2025). New soluble CSF-1R-dimeric mutein with enhanced trapping of both CSF-1 and IL-34 reduces suppressive tumor-associated macrophages in pleural mesothelioma. Journal for ImmunoTherapy of Cancer, 13(3), e010112. https://doi.org/10.1136/jitc-2024-010112
Vancouver
Joalland N, Quéméner A, Deshayes S, Humeau R, Maillasson M, LeBihan H, et al. New soluble CSF-1R-dimeric mutein with enhanced trapping of both CSF-1 and IL-34 reduces suppressive tumor-associated macrophages in pleural mesothelioma. Journal for ImmunoTherapy of Cancer. 2025;13(3):e010112. doi:10.1136/jitc-2024-010112
BibTeX
@article{Joalland2025,
author = {Joalland, Noémie and Quéméner, Agnès and Deshayes, Sophie and Humeau, Romain and Maillasson, Mike and LeBihan, Héloïse and Salama, Apolline and Fresquet, Judith and Remy, Séverine and Mortier, Erwan and Blanquart, Christophe and Guillonneau, Carole and Anegon, Ignacio},
title = {New soluble CSF-1R-dimeric mutein with enhanced trapping of both CSF-1 and IL-34 reduces suppressive tumor-associated macrophages in pleural mesothelioma},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2025},
volume = {13},
number = {3},
pages = {e010112},
doi = {10.1136/jitc-2024-010112}
}
EUVIMED